LONDON - Artelo Biosciences , Inc. (NASDAQ:ARTL), a clinical-stage biopharmaceutical company, presented new pre-clinical data on its cannabinoid-based compound, ART12.11, at the CT-CANN24 conference in London, UK, on Monday.
The data indicated that ART12.11, in its unoptimized form, showed a pharmacokinetic profile that was comparable to the FDA-approved Epidiolex®, an oral CBD solution used for controlling seizures in rare childhood disorders.
Chief Scientific Officer Dr. Andrew Yates shared the findings, revealing that ART12.11's pharmacokinetics of CBD and its metabolites matched those provided by Epidiolex. Moreover, Artelo's cocrystal composition of CBD and tetramethylpyrazine (TMP) has previously shown to outperform CBD alone in animal studies of stress-induced anxiety and depression, suggesting a potential reduction in pill burden for future oral solid formulations.
Artelo is currently developing an optimized tablet form of ART12.11, which is anticipated to offer advantages over oral solutions, including precise dosing and easier storage and transport, particularly for adolescent and adult patients. The tablet form is expected to enhance the appeal and practicality of the medication when it enters clinical studies.
ART12.11 is a proprietary cocrystal composition of CBD and TMP, which has demonstrated improved pharmacokinetics and efficacy compared to other forms of CBD in nonclinical studies. Artelo holds a U.S. patent for ART12.11 that is enforceable until December 10, 2038, and believes that the compound's consistent and improved bioavailability may lead to increased safety and efficacy in human applications.
The presentation at CT-CANN24 is part of Artelo's ongoing efforts to develop and commercialize therapeutics that modulate lipid-signaling pathways, including the endocannabinoid system, for various conditions such as anorexia, cancer, anxiety, pain, and inflammation. The company's portfolio aims to address significant unmet medical needs with its product candidates.
The information in this article is based on a press release statement from Artelo Biosciences. Investors are advised that forward-looking statements involve risks and uncertainties and are subject to change.
InvestingPro Insights
Artelo Biosciences, Inc. (NASDAQ:ARTL) continues to make strides in the development of its cannabinoid-based compound, ART12.11, with promising pre-clinical data. However, an InvestingPro analysis reveals several financial metrics and market sentiments that investors should consider:
InvestingPro Data shows that Artelo Biosciences has a market capitalization of $4.42 million USD, with a significantly low price-to-book ratio of 0.46 as of the last twelve months ending Q1 2024. This could indicate that the company's stock is potentially undervalued relative to its assets. Additionally, Artelo's stock has experienced a 1-week price total return of -10.16%, which may reflect recent market reactions to company developments or broader sector trends.
An InvestingPro Tip highlights that Artelo holds more cash than debt on its balance, which is a positive sign of financial stability and may provide the company with a cushion to fund ongoing research and development activities without relying heavily on external financing.
While the company's net income is expected to drop this year and analysts do not anticipate profitability for the current year, it's important to note that Artelo's liquid assets exceed its short-term obligations. This suggests that the company has the liquidity to meet its immediate financial commitments, which is crucial for its operations and continued investment in product development.
Investors interested in a deeper analysis of Artelo Biosciences, including additional InvestingPro Tips, can visit https://www.investing.com/pro/ARTL. There are 8 additional tips available that could provide further insights into the company's financial health and market position. Use coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription, allowing for more informed investment decisions.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.